Insight Molecular Diagnostics (IMDX) Long-Term Debt Repayments (2020 - 2022)
Historic Long-Term Debt Repayments for Insight Molecular Diagnostics (IMDX) over the last 3 years, with Q3 2022 value amounting to $575000.0.
- Insight Molecular Diagnostics' Long-Term Debt Repayments rose 5333.33% to $575000.0 in Q3 2022 from the same period last year, while for Dec 2022 it was $1.3 million, marking a year-over-year decrease of 1166.67%. This contributed to the annual value of $1.3 million for FY2022, which is 1166.67% down from last year.
- Per Insight Molecular Diagnostics' latest filing, its Long-Term Debt Repayments stood at $575000.0 for Q3 2022, which was up 5333.33% from $375000.0 recorded in Q2 2022.
- In the past 5 years, Insight Molecular Diagnostics' Long-Term Debt Repayments ranged from a high of $575000.0 in Q3 2022 and a low of $250000.0 during Q4 2020
- Over the past 3 years, Insight Molecular Diagnostics' median Long-Term Debt Repayments value was $375000.0 (recorded in 2021), while the average stood at $384375.0.
- Over the last 5 years, Insight Molecular Diagnostics' Long-Term Debt Repayments had its largest YoY gain of 5333.33% in 2022, and its largest YoY loss of 0.0% in 2022.
- Insight Molecular Diagnostics' Long-Term Debt Repayments (Quarter) stood at $250000.0 in 2020, then surged by 50.0% to $375000.0 in 2021, then surged by 53.33% to $575000.0 in 2022.
- Its Long-Term Debt Repayments was $575000.0 in Q3 2022, compared to $375000.0 in Q2 2022 and $375000.0 in Q1 2022.